Novartis, Spark in vision-loss gene therapy deal – MarketWatch
|
Novartis, Spark in vision-loss gene therapy deal
MarketWatch Novartis AG (NOVN.EB) has reached a licensing agreement with Spark Therapeutics Inc. ONCE, -2.10% to commercialize outside the U.S. a gene therapy for a form of vision loss, the companies said on Wednesday. Under the agreement, Novartis will make an … |
